Top

Clinical Reviews in Allergy & Immunology

Published in:

01-08-2017

Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review

Authors: Amelia Ruffatti, Ariela Hoxha, Maria Favaro, Marta Tonello, Anna Colpo, Umberto Cucchini, Alessandra Banzato, Vittorio Pengo

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2017

Abstract

Most investigators currently advocate prophylactic-dose heparin plus low-dose aspirin as the preferred treatment of otherwise healthy women with obstetric antiphospholipid syndrome, whilst women with a history of vascular thrombosis alone or associated with pregnancy morbidity are usually treated with therapeutic heparin doses in association with low-dose aspirin in an attempt to prevent both thrombosis and pregnancy morbidity. However, the protocols outlined above fail in about 20 % of pregnant women with antiphospholipid syndrome. Identifying risk factors associated with pregnancy failure when conventional therapies are utilized is an important step in establishing guidelines to manage these high-risk patients. Some clinical and laboratory risk factors have been found to be related to maternal–foetal complications in pregnant women on conventional therapy. However, the most efficacious treatments to administer to high-risk antiphospholipid syndrome women in addition to conventional therapy in order to avoid pregnancy complications are as yet unestablished. This is a comprehensive review on this topic and an invitation to participate in a multicentre study in order to identify the best additional treatments to be used in this subset of antiphospholipid syndrome patients.

Hughes GR (1984) The Prosser–White oration 1983. Connective tissue disease and the skin. Clin Exp Dermatol 9:535–544CrossRefPubMed

Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed

Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L (2002) Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 17:1067–1071CrossRefPubMed

Di Simone N, Marana R, Castellani R et al (2010) Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum 62:1504–1512CrossRefPubMed

Shamonki JM, Salmon JE, Hyjek E, Baergen RN (2007) Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 196:161–165CrossRef

Tong M, Viall CA, Chamley LW (2015) Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum Reprod Update 21:97–118CrossRefPubMed

Bose P, Black S, Kadyrov M et al (2005) Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 192:23–30CrossRefPubMed

Peaceman AM, Rehnberg KA (1995) The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant. Am J Obstet Gynecol 173:1391–1396CrossRefPubMed

Fishman P, Falach-Vaknin E, Sredni B et al (1996) Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am J Reprod Immunol 35:80–84CrossRefPubMed

10.

de Jesus GR, Agmon-Levin N, Andrade CA et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 13:795–813CrossRefPubMed

11.

Kutteh WH (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174:1584–1589CrossRefPubMed

12.

Rai R, Cohen H, Dave M et al (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314:253–257CrossRefPubMedPubMedCentral

13.

Franklin RD, Kutteh WH (2002) Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod 17:2981–2985CrossRefPubMed

14.

Empson M, Lassere M, Craig J, Scott J (2005) Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2:CD002859

15.

Mak A, Cheung MW, Cheak AA, Ho RC (2010) Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 9:281–288CrossRef

16.

Farquharson RG, Quenby S, Greaves M (2002) Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 100:408–413CrossRefPubMed

17.

Lassere M, Empson M (2004) Treatment of antiphospholipid syndrome in pregnancy—a systematic review of randomized therapeutic trials. Thromb Res 114:419–426CrossRefPubMed

18.

Parke A, Maier D, Wilson D, Andreoli J, Ballow M (1989) Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med 110:495–496CrossRefPubMed

19.

Wapner RJ, Cowchock FS, Shapiro SS (1989) Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions. Am J Obstet Gynecol 161:1271–1272CrossRefPubMed

20.

Ron-el R, Vinder A, Golan A et al (1993) The use of intravenous gammaglobulin, heparin and aspirin in the maintenance of pregnancy of freeze thawed embryo in a patient with lupus-type anticoagulant. Eur J Obstet Gynecol Reprod Biol 52:131–133CrossRefPubMed

21.

Kaaja R, Julkunen H, Ammälä P et al (1993) Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 72:63–66CrossRefPubMed

22.

Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, Van Assche A, Vermylen J (1994) High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost 71:741–747PubMed

23.

Somerset DA, Raine-Fenning N, Gordon C, Weaver JB, Kilby MD (1998) Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus. Eur J Obstet Gynecol Reprod Biol 79:227–229CrossRefPubMed

24.

Branch DW, Peaceman AM, Druzin M et al (2000) A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182:122–127CrossRefPubMed

25.

Stojanovich L, Mikovic Z, Mandic V, Popovich-Kuzmanovich D (2007) Treatment of antiphospholipid syndrome in pregnancy with low doses of intravenous immunoglobulin. Isr Med Assoc J 9:555–556PubMed

26.

Mar N, Kosowicz R, Hook K (2014) Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss. J Thromb Thrombolysis 38:196–200CrossRefPubMed

27.

Watanabe N, Yamaguchi K, Motomura K, HisanoM SH, Murashima A (2014) Combination therapy with anticoagulants, corticosteroids and intravenous immunoglobulin for women with severe obstetric antiphospholipid syndrome. Clin Exp Rheumatol 32:299–300PubMed

28.

Rose HL, Ho WK (2014) Management of very high risk pregnancy with secondary anti-phospholipid sindrome and triple positivity to the anti-phospholipid antibodies. J Throm Thrombolysis 38:453–456CrossRef

29.

Bramham K, Thomas M, Nelson-Piercy C et al (2011) First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 117:6948–6951CrossRefPubMed

30.

Frampton G, Cameron JS, Thom M et al (1987) Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet 2:1023–1024CrossRefPubMed

31.

Kobayashi S, Tamura N, Tsuda H et al (1992) Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy. Ann Rheum Dis 51:399–401CrossRefPubMedPubMedCentral

32.

Nakamura Y, Yoshida K, Itoh S et al (1999) Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies. Am J Reprod Immunol 41:307–311CrossRefPubMed

33.

El-Haieg DO, Zanati MF, El-Foual FM (2007) Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet 99:236–241CrossRefPubMed

34.

Ruffatti A, Marson P, Pengo V et al (2007) Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 6:196–202CrossRefPubMed

35.

Bortolati M, Marson P, Chiarelli S et al (2009) Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther Apher Dial 13:157–160CrossRefPubMed

36.

Mayer-Pickel K, Horn S, Lang U, Cervar-Zivkovic M (2015) Response to plasmapheresis measured by angiogenic factors in a woman with antiphospholipid syndrome in pregnancy. Case Rep Obstet Gynecol Article ID 123408:1–6

37.

Ruffatti A, Favaro M, Hoxha A et al (2016) Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. J Reprod Immunol 115:14–19CrossRefPubMed

38.

Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR (1996) A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 14:131–136PubMed

39.

Sailer T, Zoghlami C, Kurz C et al (2006) Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 95:796–801PubMed

40.

Matsuki Y, Atsumi T, Yamaguchi K et al (2015) Clinical features and pregnancy outcome in antiphospholipid syndrome with history of severe pregnancy complications. Mod Rheumatol 25:215–218CrossRefPubMed

41.

Bramham K, Hunt BJ, Germain S et al (2010) Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19:58–64CrossRefPubMed

42.

Fischer-Betz R, Specker C, Brinks R et al (2012) Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 21:1183–1189CrossRefPubMed

43.

Lockshin MD, Kim M, Laskin CA et al (2012) Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 64:2311–2318CrossRefPubMedPubMedCentral

44.

Simchen MJ, Dulitzki M, Rofe G et al (2011) High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand 90:1428–1433CrossRefPubMed

45.

Danowski A, de Azevedo MN, de Souza Papi JA et al (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36:1195–1199CrossRefPubMed

46.

De Carolis S, Botta A, Santucci S et al (2010) Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allergy Immunol 38:116–124CrossRefPubMed

47.

Reggia R, Ziglioli T, Andreoli L et al (2012) Primary antiphospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? Rheumatology 51:2186–2190CrossRefPubMed

48.

Danza A, Ruiz-Irastorza G, Khamashta MA (2012) Antiphospholipid sindrome in obstetrics. Best Pract Res Clin Obstet Gynaecol 26:65–76CrossRefPubMed

49.

Cervera R, Khamashta MA, Shoenfeld Y et al (2009) Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 68:1428–1432CrossRefPubMed

50.

Gris JC, Bouvier S, Molinari N et al (2012) Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 119:2624–2632CrossRefPubMed

51.

Gomez-Puerta JA, Sanin-Blair J, Galarza-Maldonado C (2009) Pregnancy and catastrophic antiphospholipid syndrome. Clin Rev Allergy Immunol 36:85–90CrossRefPubMed

52.

Costedoat-Chalumeau N, Guettrot-Imbert G, Leguern et al (2012) Pregnancy and antiphospholipid syndrome. Rev Med Interne 33:209–216CrossRefPubMed

53.

Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD (2009) Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth 9:11CrossRefPubMedPubMedCentral

54.

de Jesus GR, Rodrigues G, de Jesus NR, Levy RA (2014) Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep 16:403CrossRefPubMed

55.

Appenzeller S, Souza FH, Wagner Silva de Souza A, Shoenfeld Y, de Carvalho JF (2011) HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum 41:517–523CrossRefPubMed

56.

Pauzner R, Dulitzky M, Carp H et al (2003) Hepatic infarctions during pregnancy are associated with the antiphospholipid syndrome and in addition with complete or incomplete HELLP syndrome. J Thromb Haemost 1:1758–1763CrossRefPubMed

57.

Le Thi TD, Tieulié N, Costedoat N et al (2005) The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 64:273–278CrossRefPubMedCentral

58.

Hochfeld M, Druzin ML, Maia D, Wright J, Lambert E, McGuire J (1994) Pregnancy complicated by primary antiphospholipid antibody syndrome. Obstet Gynecol 83:804–805PubMed

59.

Sinha J, Chowdhry I, Sedan S, Barland P (2002) Bone marrow necrosis and refractory HELLP syndrome in a patient with catastrophic antiphospholipid antibody syndrome. J Rheumatol 29:195–197PubMed

60.

Koenig M, Roy M, Baccot S, Cuilleron M, de Filippis JP, Cathédras P (2005) Trombotic microangiopathy with liver, gut and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol 2:166–168CrossRef

61.

Asherson RA, Cervera R, Pierangeli SS (2007) Microangiopathic antiphospholipid syndromes (MAPS) revisited—new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol 34:1793–1795PubMed

62.

Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R (2010) Preeclampsia. Lancet 376:631–644CrossRefPubMed

63.

de Jesus GR, dos Santos FC, Oliveira CS et al (2012) Management of obstetric antiphospholipid syndrome. Curr Rheumatol Rep 14:79–86CrossRefPubMed

64.

Spegiorin LC, Galão EA, De Godoy JM et al (2007) Antiphospholipid antibodies and growth retardation in intrauterine development. Prague Med Rep 108:185–190PubMed

65.

Dadhwal V, Sharma AK, Deka D et al (2011) The obstetric outcome following treatment in a cohort of patients with antiphospholipid antibody syndrome in a tertiary care center. J Postgrad Med 57:16–19CrossRefPubMed

66.

Serrano F, Nogueira I, Borges A, Branco J (2009) Primary antiphospholipid syndrome: pregnancy outcome in a Portuguese population. Acta Reumatol Port 34:492–497PubMed

67.

Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027CrossRefPubMed

68.

Andreoli L, Fredi M, Nalli C et al (2012) Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun 38:197–208CrossRef

69.

Ruffatti A, Tonello M, Del Ross T et al (2006) Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 96:337–341PubMed

70.

Ruffatti A, Tonello M, Cavazzana A et al (2009) Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 123:482–487CrossRefPubMed

71.

Ruffatti A, Tonello M, Visentin MS et al (2011) Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology 50:1684–1689CrossRefPubMed

72.

Wijetilleka S, Scoble T, Khamashta M (2012) Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. Curr Opin Rheumatol 24:473–481CrossRefPubMed

73.

Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17CrossRefPubMed

74.

Vaquero E, Lazzarin N, Valensise H et al (2001) Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol 45:174–179CrossRefPubMed

75.

Triolo G, Ferrante A, Ciccia F et al (2003) Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent foetal loss associated with antiphospholipid antibodies. Arthritis Rheum 48:728–731CrossRefPubMed

76.

Dendrinos S, Sakkas E, Makrakis E (2009) Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 104:223–225CrossRefPubMed

77.

Sherer Y, Levy Y, Shoenfeld Y (2000) Intravenous immunoglobulin therapy of anti-phospholipid syndrome. Rheumatology (Oxford) 39:421–426CrossRef

78.

Carreras LD, Perez GN, Vega HR, Casavilla F (1988) Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet 2:393–394CrossRefPubMed

79.

Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A (2015) Intravenous immunoglobulins and antiphospholipid syndrome: how, when and why? A review of the literature. Autoimmun Rev 15:226–235CrossRefPubMed

80.

Gelfand EW (2012) Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367:2015–2025CrossRefPubMed

81.

Guidelli GM, Tenti S, Pascarelli NA, Galeazzi M, Fioravanti A (2015) Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature. Autoimmun Rev 14:659–664CrossRefPubMed

82.

Caccavo D, Vaccaro F, Ferri GM, Amoroso A, Bonomo L (1994) Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun 7:537–548CrossRefPubMed

83.

Galli M, Cortelazzo S, Barbui T (1991) In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti-idiotypic mechanism. Am J Hematol 38:184–188CrossRefPubMed

84.

Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y (1993) The effect of intravenous gammaglobulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 69:97–100CrossRefPubMed

85.

Cherin P, Marie I, Michallet M et al (2016) Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev 15:71–81CrossRefPubMed

86.

Scoble T, Wijetilleka S, Khamashta MA (2011) Management of refractory anti-phospholipid syndrome. Autoimmun Rev 10:669–673CrossRefPubMed

87.

Hauser AC, Hauser L, Pabinger-Fasching I et al (2005) The course of anticardiolipin antibody levels under immunoadsorption therapy. Am J Kidney Dis 46:446–454CrossRefPubMed

88.

Bontadi A, Ruffatti A, Marson P et al (2012) Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J Clin Apher 27:200–204CrossRefPubMed

89.

Marson P, Bagatella P, Bortolati M et al (2008) Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J Intern Med 264:201–203CrossRefPubMed

90.

Ruffatti A, Favaro M, Brucato A et al (2015) Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block. Transfus Apher Sci 53:269–278CrossRefPubMed

91.

Mekinian A, Costedoat-Chalumeau N, Masseau A et al (2015) Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? Autoimmun Rev 14:23–29CrossRefPubMed

92.

Marchetti T, Ruffatti TA, Wuillemin C, de Moerloose P, Cohen M (2014) Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost 12:910–920CrossRefPubMed

93.

Rand JH, Wu XX, Quinn AS, Taatjes DJ (2010) The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 19:460–469CrossRefPubMed

94.

Mekinian A, Lazzaroni MG, Kuzenko A (2015) The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 14:498–502CrossRefPubMed

95.

Ruffatti A, Salvan E, Del Ross T et al (2014) Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost 112:727–735CrossRefPubMed

96.

Devreese KMJ, Pierangeli SS, De Laat B, Tripodi A, Atsumi T, Ortel TL (2014) For the Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 12:792–795CrossRefPubMed

97.

Pengo V, Tripodi A, Reber G et al (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7:1737–1740CrossRefPubMed

Title: Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review
Authors: Amelia Ruffatti
Ariela Hoxha
Maria Favaro
Marta Tonello
Anna Colpo
Umberto Cucchini
Alessandra Banzato
Vittorio Pengo
Publication date: 01-08-2017
Publisher: Springer US
Published in: Clinical Reviews in Allergy & Immunology / Issue 1/2017
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-016-8571-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Female Infertility and Serum Auto-antibodies: a Systematic Review

Challenges in the Standardization of Autoantibody Testing: a Comprehensive Review

Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review

Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome—A Retrospective Analysis and a Review of Additional Treatment in Pregnancy

Air Travel, Circadian Rhythms/Hormones, and Autoimmunity

Anti-phospholipid Antibodies and Smoking: An Overview

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page